View in EDS

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Saved in:
Bibliographic Details
Title: Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Authors: Jhaveri K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York. Electronic address: jhaverik@mskcc.org., Eli LD; Clinical Development, Puma Biotechnology, Los Angeles, USA., Wildiers H; University Hospitals Leuven, Leuven, Belgium., Hurvitz SA; David Geffen School of Medicine, UCLA, Los Angeles, Santa Monica, USA., Guerrero-Zotano A; Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Unni N; UT Southwestern Medical Center, Dallas., Brufsky A; Magee-Womens Hospital of UPMC, Pittsburgh., Park H; Washington University School of Medicine, St. Louis., Waisman J; City of Hope Comprehensive Cancer Center, Duarte., Yang ES; University of Alabama at Birmingham, Birmingham, USA., Spanggaard I; Department of Oncology, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark., Reid S; Division of Hematology/Oncology (Breast Oncology), The Vanderbilt-Ingram Cancer Center, Nashville., Burkard ME; Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison., Vinayak S; Seattle Cancer Care Alliance, Seattle, USA., Prat A; Hospital Clínic de Barcelona, Barcelona, Spain., Arnedos M; Department of Medical Oncology, Gustave Roussy, Villejuif., Bidard FC; Department of Medical Oncology, UVSQ/Paris-Saclay University, Institut Curie, Saint Cloud, France., Loi S; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne; The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Australia., Crown J; St. Vincent's University Hospital, Dublin, Ireland., Bhave M; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston., Suga JM; Kaiser Permanente, Department of Medical Oncology, Vallejo, USA., Chia S; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada., Saura C; Medical Oncology Service, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona., Garcia-Saenz JÁ; Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid., Gambardella V; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia., de Miguel MJ; START Madrid - Hospital Universitario Madrid Sanchinarro, Madrid, Spain., Gal-Yam EN; Institute of Breast Oncology, Sheba Medical Center, Ramat Gan., Rapael A; Sourasky Medical Center, Tel Aviv., Stemmer SM; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva; Tel Aviv University, Tel Aviv, Israel., Ma C; Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis., Hanker AB; UT Southwestern Simmons Comprehensive Cancer Center, Dallas., Ye D; UT Southwestern Simmons Comprehensive Cancer Center, Dallas., Goldman JW; UCLA Hematology & Oncology, Santa Monica., Bose R; Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis., Peterson L; Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis., Bell JSK; Tempus Labs, Chicago, USA., Frazier A; Clinical Development, Puma Biotechnology, Los Angeles, USA., DiPrimeo D; Clinical Development, Puma Biotechnology, Los Angeles, USA., Wong A; Clinical Development, Puma Biotechnology, Los Angeles, USA., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas., Solit DB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2023 Oct; Vol. 34 (10), pp. 885-898. Date of Electronic Publication: 2023 Aug 18.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37597578
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jhaveri+K%22">Jhaveri K</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York. Electronic address: jhaverik@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Eli+LD%22">Eli LD</searchLink>; Clinical Development, Puma Biotechnology, Los Angeles, USA.<br /><searchLink fieldCode="AU" term="%22Wildiers+H%22">Wildiers H</searchLink>; University Hospitals Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Hurvitz+SA%22">Hurvitz SA</searchLink>; David Geffen School of Medicine, UCLA, Los Angeles, Santa Monica, USA.<br /><searchLink fieldCode="AU" term="%22Guerrero-Zotano+A%22">Guerrero-Zotano A</searchLink>; Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Unni+N%22">Unni N</searchLink>; UT Southwestern Medical Center, Dallas.<br /><searchLink fieldCode="AU" term="%22Brufsky+A%22">Brufsky A</searchLink>; Magee-Womens Hospital of UPMC, Pittsburgh.<br /><searchLink fieldCode="AU" term="%22Park+H%22">Park H</searchLink>; Washington University School of Medicine, St. Louis.<br /><searchLink fieldCode="AU" term="%22Waisman+J%22">Waisman J</searchLink>; City of Hope Comprehensive Cancer Center, Duarte.<br /><searchLink fieldCode="AU" term="%22Yang+ES%22">Yang ES</searchLink>; University of Alabama at Birmingham, Birmingham, USA.<br /><searchLink fieldCode="AU" term="%22Spanggaard+I%22">Spanggaard I</searchLink>; Department of Oncology, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Reid+S%22">Reid S</searchLink>; Division of Hematology/Oncology (Breast Oncology), The Vanderbilt-Ingram Cancer Center, Nashville.<br /><searchLink fieldCode="AU" term="%22Burkard+ME%22">Burkard ME</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison.<br /><searchLink fieldCode="AU" term="%22Vinayak+S%22">Vinayak S</searchLink>; Seattle Cancer Care Alliance, Seattle, USA.<br /><searchLink fieldCode="AU" term="%22Prat+A%22">Prat A</searchLink>; Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Arnedos+M%22">Arnedos M</searchLink>; Department of Medical Oncology, Gustave Roussy, Villejuif.<br /><searchLink fieldCode="AU" term="%22Bidard+FC%22">Bidard FC</searchLink>; Department of Medical Oncology, UVSQ/Paris-Saclay University, Institut Curie, Saint Cloud, France.<br /><searchLink fieldCode="AU" term="%22Loi+S%22">Loi S</searchLink>; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne; The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Crown+J%22">Crown J</searchLink>; St. Vincent's University Hospital, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Bhave+M%22">Bhave M</searchLink>; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston.<br /><searchLink fieldCode="AU" term="%22Suga+JM%22">Suga JM</searchLink>; Kaiser Permanente, Department of Medical Oncology, Vallejo, USA.<br /><searchLink fieldCode="AU" term="%22Chia+S%22">Chia S</searchLink>; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.<br /><searchLink fieldCode="AU" term="%22Saura+C%22">Saura C</searchLink>; Medical Oncology Service, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.<br /><searchLink fieldCode="AU" term="%22Garcia-Saenz+JÁ%22">Garcia-Saenz JÁ</searchLink>; Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid.<br /><searchLink fieldCode="AU" term="%22Gambardella+V%22">Gambardella V</searchLink>; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia.<br /><searchLink fieldCode="AU" term="%22de+Miguel+MJ%22">de Miguel MJ</searchLink>; START Madrid - Hospital Universitario Madrid Sanchinarro, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Gal-Yam+EN%22">Gal-Yam EN</searchLink>; Institute of Breast Oncology, Sheba Medical Center, Ramat Gan.<br /><searchLink fieldCode="AU" term="%22Rapael+A%22">Rapael A</searchLink>; Sourasky Medical Center, Tel Aviv.<br /><searchLink fieldCode="AU" term="%22Stemmer+SM%22">Stemmer SM</searchLink>; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva; Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Ma+C%22">Ma C</searchLink>; Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis.<br /><searchLink fieldCode="AU" term="%22Hanker+AB%22">Hanker AB</searchLink>; UT Southwestern Simmons Comprehensive Cancer Center, Dallas.<br /><searchLink fieldCode="AU" term="%22Ye+D%22">Ye D</searchLink>; UT Southwestern Simmons Comprehensive Cancer Center, Dallas.<br /><searchLink fieldCode="AU" term="%22Goldman+JW%22">Goldman JW</searchLink>; UCLA Hematology & Oncology, Santa Monica.<br /><searchLink fieldCode="AU" term="%22Bose+R%22">Bose R</searchLink>; Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis.<br /><searchLink fieldCode="AU" term="%22Peterson+L%22">Peterson L</searchLink>; Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis.<br /><searchLink fieldCode="AU" term="%22Bell+JSK%22">Bell JSK</searchLink>; Tempus Labs, Chicago, USA.<br /><searchLink fieldCode="AU" term="%22Frazier+A%22">Frazier A</searchLink>; Clinical Development, Puma Biotechnology, Los Angeles, USA.<br /><searchLink fieldCode="AU" term="%22DiPrimeo+D%22">DiPrimeo D</searchLink>; Clinical Development, Puma Biotechnology, Los Angeles, USA.<br /><searchLink fieldCode="AU" term="%22Wong+A%22">Wong A</searchLink>; Clinical Development, Puma Biotechnology, Los Angeles, USA.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; UT Southwestern Simmons Comprehensive Cancer Center, Dallas.<br /><searchLink fieldCode="AU" term="%22Solit+DB%22">Solit DB</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2023 Oct; Vol. 34 (10), pp. 885-898. <i>Date of Electronic Publication: </i>2023 Aug 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37597578
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2023.08.003
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 885
    Titles:
      – TitleFull: Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jhaveri K
      – PersonEntity:
          Name:
            NameFull: Eli LD
      – PersonEntity:
          Name:
            NameFull: Wildiers H
      – PersonEntity:
          Name:
            NameFull: Hurvitz SA
      – PersonEntity:
          Name:
            NameFull: Guerrero-Zotano A
      – PersonEntity:
          Name:
            NameFull: Unni N
      – PersonEntity:
          Name:
            NameFull: Brufsky A
      – PersonEntity:
          Name:
            NameFull: Park H
      – PersonEntity:
          Name:
            NameFull: Waisman J
      – PersonEntity:
          Name:
            NameFull: Yang ES
      – PersonEntity:
          Name:
            NameFull: Spanggaard I
      – PersonEntity:
          Name:
            NameFull: Reid S
      – PersonEntity:
          Name:
            NameFull: Burkard ME
      – PersonEntity:
          Name:
            NameFull: Vinayak S
      – PersonEntity:
          Name:
            NameFull: Prat A
      – PersonEntity:
          Name:
            NameFull: Arnedos M
      – PersonEntity:
          Name:
            NameFull: Bidard FC
      – PersonEntity:
          Name:
            NameFull: Loi S
      – PersonEntity:
          Name:
            NameFull: Crown J
      – PersonEntity:
          Name:
            NameFull: Bhave M
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Suga JM
      – PersonEntity:
          Name:
            NameFull: Chia S
      – PersonEntity:
          Name:
            NameFull: Saura C
      – PersonEntity:
          Name:
            NameFull: Garcia-Saenz JÁ
      – PersonEntity:
          Name:
            NameFull: Gambardella V
      – PersonEntity:
          Name:
            NameFull: de Miguel MJ
      – PersonEntity:
          Name:
            NameFull: Gal-Yam EN
      – PersonEntity:
          Name:
            NameFull: Rapael A
      – PersonEntity:
          Name:
            NameFull: Stemmer SM
      – PersonEntity:
          Name:
            NameFull: Ma C
      – PersonEntity:
          Name:
            NameFull: Hanker AB
      – PersonEntity:
          Name:
            NameFull: Ye D
      – PersonEntity:
          Name:
            NameFull: Goldman JW
      – PersonEntity:
          Name:
            NameFull: Bose R
      – PersonEntity:
          Name:
            NameFull: Peterson L
      – PersonEntity:
          Name:
            NameFull: Bell JSK
      – PersonEntity:
          Name:
            NameFull: Frazier A
      – PersonEntity:
          Name:
            NameFull: DiPrimeo D
      – PersonEntity:
          Name:
            NameFull: Wong A
      – PersonEntity:
          Name:
            NameFull: Arteaga CL
      – PersonEntity:
          Name:
            NameFull: Solit DB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2023 Oct
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1569-8041
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology
              Type: main
ResultId 1